1. Home
  2. IKNA vs BZFD Comparison

IKNA vs BZFD Comparison

Compare IKNA & BZFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • BZFD
  • Stock Information
  • Founded
  • IKNA 2016
  • BZFD 2006
  • Country
  • IKNA United States
  • BZFD United States
  • Employees
  • IKNA N/A
  • BZFD N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • BZFD Movies/Entertainment
  • Sector
  • IKNA Health Care
  • BZFD Consumer Discretionary
  • Exchange
  • IKNA Nasdaq
  • BZFD Nasdaq
  • Market Cap
  • IKNA 61.8M
  • BZFD 72.8M
  • IPO Year
  • IKNA 2021
  • BZFD N/A
  • Fundamental
  • Price
  • IKNA $1.13
  • BZFD $1.86
  • Analyst Decision
  • IKNA Buy
  • BZFD
  • Analyst Count
  • IKNA 2
  • BZFD 0
  • Target Price
  • IKNA $3.00
  • BZFD N/A
  • AVG Volume (30 Days)
  • IKNA 96.4K
  • BZFD 259.6K
  • Earning Date
  • IKNA 05-08-2025
  • BZFD 05-07-2025
  • Dividend Yield
  • IKNA N/A
  • BZFD N/A
  • EPS Growth
  • IKNA N/A
  • BZFD N/A
  • EPS
  • IKNA N/A
  • BZFD 0.34
  • Revenue
  • IKNA N/A
  • BZFD $188,899,000.00
  • Revenue This Year
  • IKNA N/A
  • BZFD $89.62
  • Revenue Next Year
  • IKNA N/A
  • BZFD $4.50
  • P/E Ratio
  • IKNA N/A
  • BZFD $5.51
  • Revenue Growth
  • IKNA N/A
  • BZFD N/A
  • 52 Week Low
  • IKNA $0.97
  • BZFD $1.61
  • 52 Week High
  • IKNA $1.94
  • BZFD $5.68
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 43.57
  • BZFD 47.05
  • Support Level
  • IKNA $1.22
  • BZFD $1.73
  • Resistance Level
  • IKNA $1.29
  • BZFD $2.11
  • Average True Range (ATR)
  • IKNA 0.09
  • BZFD 0.15
  • MACD
  • IKNA -0.01
  • BZFD 0.02
  • Stochastic Oscillator
  • IKNA 23.33
  • BZFD 48.42

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About BZFD BuzzFeed Inc.

BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.

Share on Social Networks: